{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "NOUVEAUX TRAITEMENTS ET SURVIE DANS LE CANCER PULMONAIRE. Les paradigmes du traitement du cancer du poumon ont drastiquement chang\u00e9 au d\u00e9but des ann\u00e9es 2000, notamment avec la d\u00e9couverte de drivers oncog\u00e9niques ciblables tels que l\u2019 epidermal growth factor receptor (EGFR,) ou r\u00e9cepteur du facteur de croissance \u00e9pidermique, et l\u2019a naplasic lymphome kinase (ALK). L\u2019incidence et la mortalit\u00e9 ont toutes deux diminu\u00e9es gr\u00e2ce \u00e0 l\u2019introduction de traitements sp\u00e9cifiques. Ces th\u00e9rapies cibl\u00e9es ont \u00e9volu\u00e9 depuis, et l\u2019immunoth\u00e9rapie est devenue la pierre angulaire du traitement des carcinomes bronchiques non \u00e0 petites cellules. Les indications des th\u00e9rapies syst\u00e9miques s\u2019\u00e9tendent maintenant aux stades localis\u00e9s, autrefois l\u2019apanage de la chirurgie et de la radioth\u00e9rapie. Les principales avanc\u00e9es th\u00e9rapeutiques durant ces derni\u00e8res ann\u00e9es ont permis une am\u00e9lioration de la survie et de la qualit\u00e9 de vie des patients atteints d\u2019un cancer pulmonaire."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36820443",
  "DateCompleted": {
    "Year": "2023",
    "Month": "02",
    "Day": "27"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "02",
    "Day": "27"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "fre"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "2101-017X",
      "JournalIssue": {
        "Volume": "73",
        "Issue": "1",
        "PubDate": {
          "Year": "2023",
          "Month": "Jan"
        }
      },
      "Title": "La Revue du praticien",
      "ISOAbbreviation": "Rev Prat"
    },
    "ArticleTitle": "[News treatments and survival in lung cancer].",
    "Pagination": {
      "StartPage": "7",
      "EndPage": "12",
      "MedlinePgn": "7-12"
    },
    "Abstract": {
      "AbstractText": [
        "NEW TREATMENTS AND SURVIVAL IN LUNG CANCER. Treatment paradigm for non-squamous cell lung cancer (NSCLC) has evolved dramatically in the early 2000s, mainly because of the identification of targetable oncogenes such as EGFR (epidermal growth factor receptor) and ALK (anaplasic lymphome kinase). Incidence and mortality have both declined thanks to the development of novel therapies. Since major diagnosis and therapeutics were made, and immune-based therapies are the new corner stone of non-small cell lung cancer's treatment. Systemic drugs are no longer limited to advanced stages, as they are now standing alongside surgery and radiotherapy. Recent major therapeutic advances have improved survival and quality of life among lung cancer patients."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de pneumologie, h\u00f4pital Louis-Pradel, Hospices civils de Lyon, Lyon, France."
          }
        ],
        "LastName": "Lamkhioued",
        "ForeName": "Mehdi",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de pneumologie, h\u00f4pital Louis-Pradel, Hospices civils de Lyon, Lyon, France."
          }
        ],
        "LastName": "Pierret",
        "ForeName": "Thomas",
        "Initials": "T"
      }
    ],
    "PublicationTypeList": [
      "English Abstract",
      "Journal Article"
    ],
    "VernacularTitle": "Nouveaux traitements et survie dans les cancers pulmonaires."
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Rev Prat",
    "NlmUniqueID": "0404334",
    "ISSNLinking": "0035-2640"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Protein Kinase Inhibitors"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Lung Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Carcinoma, Non-Small-Cell Lung"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Quality of Life"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mutation"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Protein Kinase Inhibitors"
    }
  ],
  "CoiStatement": "M. Lamkhioued d\u00e9clare n\u2019avoir aucun lien d\u2019int\u00e9r\u00eats. T. Pierret d\u00e9clare avoir des liens d\u2019int\u00e9r\u00eats avec Pfizer, Takeda, BMS et Janssen."
}